Grant Number:	5R37CA263320-02 Interpret this number
Primary Investigator:	Mukherjee, Semanti
Organization:	Sloan-Kettering Inst Can Research
Project Title:	Discovery and Characterization of Clinically Actionable Germline Mutations in DNA Damage Repair (DDR) Pathway Genes in Lung Cancer
Fiscal Year:	2023

Project Summary/Abstract Lung cancer is the leading cause of cancer-related deaths worldwide, with a 5-year survival rate of 15%. Only a small proportion (16%) of lung cancer cases are diagnosed at an early stage, when it is more likely to be curable, thus we need improved strategies to identify high-risk individuals for intensive surveillance. Although cigarette smoking and other environmental factors are risks for lung cancer, it is estimated that 10-25% of lung cancers occur in never-smokers, highlighting the potential role of inherited genetic factors in lung cancer. Familial lung cancer as well as genome wide association studies have identified few lung cancer predisposing genes, which only explains 14% of all inherited risk for lung cancer. Hence, most of the genetic risk for lung cancer remains unexplained. With the adven t of the next-generation sequencing technologies, emerging evidence suggests the contribution of pathogenic germline mutations in DNA damage repair (DDR) genes in lung cancer susceptibility and etiology. Our preliminary data shows that about 6.8% of lung can cer patients harbored pathogenic mutations in DDR genes including high and moderate penetrant mutations in ATM, BRCA2, CHEK2, ERCC2, NBN and TP53. We hypothesize that the genetic alternations in DDR genes may modify the intrinsic and extrinsic (tobacco smoking or environmental) risk factors of lung cancer. The objectives of our proposed study are to determine the clinical significance of inherited mutations in DDR genes in lung cancer, study the interplay between germline-somatic mutational architecture and functionally characterize them to understand the mechanism of lung cancer susceptibility. Our findings will inform clinical and preventive management by elucidating genotype-phenotype correlations, penetrance (risk) modification, and clinical outcomes in genetically defined cohorts. For the proposed study, we will leverage the ongoing MSK-IMPACT initiative, an institution-wide effort to perform genomic testing using paired tumor–normal tissue samples in 10,000 patients with lung cancers as well as whole exome sequencing for a selected 400 lung cancer patients who had either family history of any cancer, or early diagnosis (age at diagnosis <50 years) or personal history of multiple primary tumors. In aim 1, we will discover germline mutations in DDR genes using novel analytical framework by integrating germline-somatic data for variant interpretation. We will replicate our findings in a case-control cohort in collaboration with the International Lung Cancer Consortium and England Genomics UK and determine risk associated with lung cancer in a case-control cohort and the pattern of inheritance in families (Aim 2). We will establish the clinical and functional significance of the germline mutations using the CRISPR gene editing approach and generate patient- derived xenograph (PDX) models from patients carrying germline mutations in DDR genes to test the therapeutic options; this will open the new paradigm of research and treatment options for lung cancer guidelines for lung cancer patients and their family members (cascade testing) for early detection.





None